Bolt Biotherapeutics, Inc.(BOLT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Bolt Biotherapeutics, Inc. (BOLT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BOLT at 11.3/100 on a 32-signal composite quality model, placing it at rank #2,901 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Bolt Biotherapeutics, Inc. reports quarterly revenue of $5.0K, net income of $-7.7M. Top institutional holders of BOLT by reported 13-F value include Sofinnova Ventures, RENAISSANCE TECHNOLOGIES, Vivo Capital, based on the most recent SEC filings. BOLT trades on the Nasdaq exchange and files with the SEC under CIK 1641281. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BOLT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bolt Biotherapeutics, Inc. directly from SEC EDGAR.